Introduction What Can We Offer? Workflow Published Data Why Choose Us? FAQs Featured Services Featured Products
Factor I Development Service: Empowering Your Complement-Targeted Therapeutics!
Are you currently facing challenges in achieving precise regulation of the alternative pathway or struggling with the degradation of C3b/C4b in complex serum environments? Our Factor I Development Service helps you bypass the limitations of traditional complement inhibitors and achieve highly specific proteolytic control through our proprietary mammalian expression systems and advanced protein engineering platforms.
Contact our team to get an inquiry now!
Introduction of Factor I Development
Complement Factor I (CFI) is an 88-kDa serine protease that functions as the central brake for all three complement pathways. Rather than a single chain, it exists as a disulfide-linked heterodimer composed of a heavy chain (~50 kDa) and a catalytic light chain (~38 kDa). The architectural complexity of the heavy chain is defined by a unique mosaic of structural motifs, including the FIMAC domain, an SRCR domain, and two LDLRA regions. These modules are not merely structural; they are indispensable for coordinating interactions between the protease, its substrates, and essential regulatory cofactors.
Fig.1 Overview of complement factor I (CFI) function.1,3
A defining characteristic of CFI is its "zymogen-like" state. Unlike many proteases that require physical cleavage for activation, CFI possesses a pre-assembled catalytic triad that stays enzymatically dormant until it is incorporated into a ternary complex. This biological trigger is only pulled when CFI encounters a target—C3b or C4b—alongside a necessary cofactor such as Factor H, C4BP, or MCP (CD46). This sophisticated allosteric control serves as a fundamental evolutionary barrier, restricting proteolysis to specific host surfaces while preventing the dangerous, systemic depletion of complement components.
Evidence from clinical research and genomic studies confirms that abnormalities in the CFI gene underpin various severe immunopathologies. Notable examples include Atypical Hemolytic Uremic Syndrome (aHUS) and Age-Related Macular Degeneration (AMD). In these conditions, impaired C3b degradation leads to an uncontrolled alternative pathway loop, fueling chronic inflammation and resulting in localized tissue failure in the ocular and renal systems. Consequently, creating optimized Factor I variants, recombinant replacements, and specific allosteric enhancers has emerged as a high-priority strategy in modern precision immunology.
Application
The utilization of Factor I technologies, customized variants, and rigorous analytical tools is fundamental across diverse biomedical landscapes:
Sustained Replacement Therapy
Offering a practical path for patients suffering from primary CFI deficiency. By reinstating normal physiological concentrations of this enzyme, clinicians can halt the uncontrolled "consumption" of C3, which in turn diminishes the risk of severe, recurring bacterial infections and prevents the cascading effects of systemic inflammation.
Targeted Ocular Interventions
Tackling the massive unmet clinical need in dry AMD and Geographic Atrophy (GA). We facilitate the design of hyper-functional, long-lasting CFI variants intended for local delivery into the eye. These proteins are engineered to break down C3b specifically within the subretinal microenvironment, obstructing the path toward chronic, complement-driven damage of the retinal pigment epithelium.
Refined Autoimmune Modulation
Exploiting the natural inhibitory capacity of CFI to dampen localized inflammatory responses in complex disorders. This involves the creation of CFI-based fusion constructs that can be directed toward specific tissues, offering a nuanced approach to controlling hyper-inflammation in conditions like Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis.
Reliable Diagnostic Benchmarking
Establishing high-fidelity reference materials for clinical laboratories. Our ultrapure CFI serves as a cornerstone in developing sensitive diagnostic platforms to evaluate complement hemolytic performance (CH50/AH50) and to track specific factor levels in patient samples, ensuring high-resolution disease monitoring.
Mitigating Reperfusion-Linked Injury
Delivering a powerful mechanism to safeguard organs during surgical procedures and transplants. By curbing the rapid, heavy accumulation of C3b that occurs when blood flow returns to oxygen-deprived tissues, CFI-centered therapeutics can notably lower post-surgical complications and boost graft health in cardiac and renal transplantation.
What Can We Offer?
We provide a specialized catalog of products and services tailored to Factor I research:
-
Recombinant Human Factor I: Available in various formats, including tagged and tag-free versions.
-
CFI Mutant Library Construction: Development of gain-of-function or loss-of-function variants for mechanistic studies.
-
Factor I Functional Assays: High-throughput screening of CFI activity in patient sera or drug-treated samples.
-
Custom Antibody Development: Specific antibodies against the heavy or light chains of Factor I for IHC and ELISA applications.
Workflow
01
Construct Design & Optimization: We perform codon optimization and signal peptide selection to ensure efficient secretion in HEK293 or CHO systems, specifically managing the complex disulfide-linked heterodimer structure of CFI.
02
High-Titer Expression: Utilization of transient and stable expression platforms to produce the 88 kDa heterodimer with correct post-translational modifications (six Asn-linked glycans).
03
Advanced Purification: Multistep chromatography (Affinity, Ion Exchange, and SEC) to isolate the mature, active enzyme from truncated or misfolded variants.
04
Functional Validation: Rigorous enzymatic assays measuring the cleavage of C3b into iC3b and C4b into C4d in the presence of cofactors like Factor H or CR1.
05
Characterization & Stability Testing: Comprehensive analysis of purity (SDS-PAGE/HPLC), endotoxin levels, and long-term storage stability.
Published Data
Fig.2 Schematic of the mature FI protein with mutations analyzed in this study.2,3
Recent research highlights groundbreaking advancements in engineering Complement Factor I (CFI) to enhance its regulatory potency. The study focused on overcoming the inherent "low activity" of native Factor I by introducing specific mutations in the heavy chain domains (FIMAC and SRCR) and the serine protease light chain. Using high-throughput site-directed mutagenesis and mammalian expression systems, researchers identified a specific variant, CFI-V7, which incorporated a combination of five strategic amino acid substitutions.
The experimental results were significant: in surface plasmon resonance (SPR) assays, the engineered CFI-V7 exhibited a 5-fold increase in binding affinity for the C3b: Factor H complex compared to wild-type CFI. More importantly, in functional proteolytic cleavage assays, this variant demonstrated a 3- to 4-fold increase in the catalytic rate for the inactivation of C3b into iC3b. When tested in a modified hemolytic assay using human serum, the engineered Factor I showed superior protection against complement-mediated lysis, effectively suppressing the alternative pathway amplification loop at significantly lower concentrations than the native protein. These results provide a robust proof-of-concept for using engineered CFI variants as potent therapeutic agents for C3-glomerulopathy and Age-Related Macular Degeneration (AMD).
Why Choose Us?
Choosing Creative Biolabs means partnering with a leader in complement immunology.
-
Unrivaled Expertise: Our scientists have specialized in the "zymogen-to-active" transition of CFI for over two decades.
-
High-Fidelity Post-Translational Modification: Factor I requires complex glycosylation and disulfide bridging; our optimized mammalian platforms ensure "Published Data" levels of bioactivity.
-
Scalability: From pilot-scale research to large-scale production, we maintain batch-to-batch consistency.
-
Successful Track Record: We have supported over 50 complement-related projects, including the development of novel CFI-cofactor fusion proteins.
FAQs
Q: Why is mammalian expression preferred for Factor I development?
A: Factor I requires extensive post-translational modifications, including the addition of six Asn-linked glycans and the precise proteolytic cleavage of a linker sequence to form the active heterodimer. Only mammalian systems like HEK293 or CHO can reliably perform these complex steps, ensuring the resulting protein is biologically active and structurally accurate.
Q: Can Factor I be used to inhibit the classical pathway?
A: Yes. While often discussed in the context of the alternative pathway, Factor I is also responsible for the cleavage of C4b into C4d. By inactivating C4b, Factor I effectively terminates the classical and lectin pathway C3 convertases, providing broad-spectrum regulation.
Q: What is the difference between Factor I "zymogen-like" status and traditional proenzymes?
A: Unlike traditional proenzymes (like trypsinogen) that require a proteolytic cut to become active, Factor I circulates in a fully processed but inactive conformation. Its activity is triggered allosterically only when it binds to its substrate and a cofactor simultaneously, which acts as a safety mechanism to prevent non-specific systemic activity.
Q: How do you ensure the stability of recombinant Factor I during shipping?
A: We conduct rigorous stability testing and utilize optimized buffer systems (often involving specific pH and salt concentrations) to prevent aggregation. Products are typically shipped on dry ice or in specialized lyophilized formats to maintain maximum enzymatic potency.
Q: Are there any specific precautions for using Factor I in serum-based assays?
A: When adding exogenous Factor I to serum, one must consider the endogenous levels and the availability of cofactors (Factor H or C4BP). We recommend a titration series to determine the optimal concentration that achieves regulation without over-suppressing the intended immune response of your specific assay.
Creative Biolabs is your premier partner for Factor I Development, providing end-to-end solutions from molecular engineering to high-purity protein production. Our deep understanding of complement regulation ensures that your project benefits from the highest standards of scientific rigor and technical excellence. Creative Biolabs provides comprehensive Factor I-functional services, including custom assay development, functional testing, and data analysis, tailored to meet your research needs and enhance your study outcomes.
Featured Services
Featured Products
References
-
Nanthapisal, Sira et al. "Cutaneous Vasculitis and Recurrent Infection Caused by Deficiency in Complement Factor I." Frontiers in immunology vol. 9 735. 11 Apr. 2018, https://doi.org/10.3389/fimmu.2018.00735
-
Gerogianni, Alexandra et al. "Functional evaluation of complement factor I variants by immunoassays and SDS-PAGE." Frontiers in immunology vol. 14 1279612. 26 Oct. 2023, https://doi.org/10.3389/fimmu.2023.1279612
-
Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only.
Related Sections:
